Evidence map›Paper›PMID 33840047›Full record

ArticleClinical & translational oncology : official publication of the Federation of Spanish Oncology Societies and of the National Cancer Institute of Mexico2021

A multi-institutional analysis of fractionated versus single-fraction stereotactic body radiotherapy (SBRT) in the treatment of primary lung tumors: a comparison between two antipodal fractionations.

F Alongi, L Nicosia, V Figlia, V De Sanctis, R Mazzola, N Giaj-Levra, C Reverberi, M Valeriani, M F Osti

Registry-linked trialAbstract readComparative StudyMulticenter Study
PubMed Publisher
In one paragraph

Article in Clinical & translational oncology : official publication of the Federation of Spanish Oncology Societies and of the National Cancer Institute of Mexico, 2021. The graph could read no effect estimate from its abstract, so it casts no vote on the map. It is linked to trial NCT07441941 (Quality-of-Life Assessment Following Single-Fraction Stereotactic Radiotherapy), which is not on this map. Cited by 4 papers.

0numbers the graph read from it
0cells of the map it votes in
4citing papers in PubMed
0.4field-weighted citation impact, top 36% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

NCT07441941 recruitingnot on this mapstarted 2026, after this paper: background citation

Quality-of-Life Assessment Following Single-Fraction Stereotactic Radiotherapy (SF-SBRT) for Inoperable Primary and Oligometastatic Lung Tumor

TypeobservationalSponsorInstitut du Cancer de Montpellier - Val d'AurelleRan2026 to 2028Enrolled190ConditionsOligometastatic Lung Tumor, NSCLC (Non-small Cell Lung Cancer), SBRT
3 · Its place in the literature

Who cites it

4 citing papers in PubMed, 3 citations in OpenAlex.

  1. Review
  2. Article
  3. Article
  4. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

9 authors at 2 institutions in 1 country.

F Alongi *Advanced Radiation Oncology Department, IRCCS Sacro Cuore Don Calabria Hospital, Cancer Care Center, via Don Sempreboni 5, 37034, Verona, Negrar, Italy.
L Nicosia *Advanced Radiation Oncology Department, IRCCS Sacro Cuore Don Calabria Hospital, Cancer Care Center, via Don Sempreboni 5, 37034, Verona, Negrar, Italy. lucanicosia.rg@gmail.com.ORCID http://orcid.org/0000-0002-0731-8041
V FigliaAdvanced Radiation Oncology Department, IRCCS Sacro Cuore Don Calabria Hospital, Cancer Care Center, via Don Sempreboni 5, 37034, Verona, Negrar, Italy.
V De SanctisDepartment of Radiation Oncology, Sant'Andrea Hospital, "Sapienza" University of Rome, Rome, Italy.
R MazzolaAdvanced Radiation Oncology Department, IRCCS Sacro Cuore Don Calabria Hospital, Cancer Care Center, via Don Sempreboni 5, 37034, Verona, Negrar, Italy.
N Giaj-LevraAdvanced Radiation Oncology Department, IRCCS Sacro Cuore Don Calabria Hospital, Cancer Care Center, via Don Sempreboni 5, 37034, Verona, Negrar, Italy.
C ReverberiDepartment of Radiation Oncology, Sant'Andrea Hospital, "Sapienza" University of Rome, Rome, Italy.
M ValerianiDepartment of Radiation Oncology, Sant'Andrea Hospital, "Sapienza" University of Rome, Rome, Italy.
M F OstiDepartment of Radiation Oncology, Sant'Andrea Hospital, "Sapienza" University of Rome, Rome, Italy.
Ospedale Sacro Cuore Don Calabria · ITSapienza University of Rome · IT

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

objectivesStereotactic body radiotherapy (SBRT) is a consolidate treatment for inoperable early-stage lung tumors, usually delivered in single or multi-fraction regimens. We aimed to compare these two approaches in terms of local effectiveness, safety and survival. MATERIALS AND

methodsPatients affected by medically inoperable early-stage lung tumor were treated at two Institutions with two different schedules: 70 Gy in ten fractions (TF) (BED10: 119 Gy) or 30 Gy in single fraction (SF) (BED10: 120 Gy).

results73 patients were treated with SBRT delivered with two biological equivalent schedules: SF (44) and TF (29). The median follow-up was 34 months (range 3-81 months). Three-year Overall survival (OS) was 57.9%, 3-year cancer-specific survival (CSS) was 77.2%, with no difference between treatment groups. Three-year progression-free survival (LPFS) was 88.9% and did not differs between SF and TF. Overall, four cases (5.4%) of acute grade ≥ 3 pneumonitis occurred. No differences in acute and late toxicity between the two groups were detected.

conclusionSF and TF seems to be equally safe and effective in the treatment of primary inoperable lung tumors especially for smaller lesion. The SF may be preferentially offered to reduce patient access to hospital with no negative impact on tumor control and survival.

Indexed as

AgedAged, 80 and overDose Fractionation, RadiationEsophagitisFemaleFollow-Up StudiesHumansLung NeoplasmsMaleMiddle AgedNeoplasm Recurrence, LocalProgression-Free SurvivalRadiation PneumonitisRadiosurgeryRadiotherapy DosageTime FactorsEarly-stage NSCLCLocal controlSABRSingle fractionStereotactic body radiotherapy

Identifiers

PMID33840047
OpenAlexW3155012093

What OpenQuestion holds

Textmetadata
Read underepoch 390

Registered trials

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.